Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. XLO
XLO logo

XLO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Xilio Therapeutics Inc (XLO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
8.790
1 Day change
0.46%
52 Week Range
12.740
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Xilio Therapeutics (XLO) is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who is impatient and wants a direct entry. The stock has a small positive daily move, but the broader technical setup is still bearish, there is no strong proprietary buy signal, and there are no fresh news or financial catalysts to support an immediate purchase. My direct view: hold off for now rather than buy today.

Technical Analysis

XLO is trading at 8.13, up 1.75% on the day, but the trend is still weak underneath the surface. MACD histogram is -0.0286 and remains below zero, which suggests momentum is still slightly negative even though it is contracting. RSI_6 at 54.05 is neutral, so there is no oversold bargain signal. The moving-average structure is bearish with SMA_200 > SMA_20 > SMA_5, showing the stock is still in a longer-term downtrend or recovery phase rather than a confirmed uptrend. Key levels: pivot 8.026, resistance 8.408 then 8.644, support 7.644 then 7.408. Price is only slightly above pivot, so the move is not yet strong enough to call a clean trend reversal. Similar pattern data suggests mixed near-term behavior: slight upside probability next day, but weaker expected performance over the next week.

Positive Catalysts

  • The stock is showing a modest positive daily price change, which indicates some near-term buying interest. The latest pattern-based estimate suggests potential upside over the next month. However, there are no recent news catalysts, no strong AI Stock Picker signal, and no SwingMax entry signal to reinforce momentum.

Neutral/Negative Catalysts

  • No news in the recent week means there is no event-driven catalyst supporting the stock right now. Technicals remain bearish overall due to the SMA alignment and negative MACD histogram. Hedge funds are neutral and insiders are neutral, so there is no visible smart-money accumulation. No recent congress trading data is available. AI Stock Picker shows no signal today, and SwingMax shows no recent signal.

Financial Performance

No usable financial snapshot was provided because of an error, so the latest quarter financial performance cannot be assessed reliably. The quarter season and growth trends are therefore unavailable from the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no evidence here of improving Wall Street sentiment. Based on the available information, the pros view is limited because there are no fresh upgrades, target increases, or positive coverage updates. The cons view is stronger: lack of news, lack of valuation support, neutral trading activity, and bearish technical structure all argue against an immediate buy.

Wall Street analysts forecast XLO stock price to rise
Analyst Rating
0
Wall Street analysts forecast XLO stock price to rise
Buy
Hold
Sell
0
Current: 8.750
sliders
Low
0
Averages
0
High
0
0
Current: 8.750
sliders
Low
0
Averages
0
High
0
Leerink
Outperform
initiated
$72
AI Analysis
2025-08-06
Reason
Leerink
Price Target
$72
AI Analysis
2025-08-06
initiated
Outperform
Reason
Leerink initiated coverage of Xilio Therapeutics with an Outperform rating and $72 price target. The company's lead program vilastobart, a conditionally masked CTLA-4 antagonist, has shown proof-of-concept efficacy in relapsed / refractory microsatellite stable non-liver metastatic colorectal cancer, a large indication, the analyst tells investors in a research note. The firm believes Xilio is among the industry leaders of developing protease-masked biologics.

People Also Watch